Complete financial analysis of Chaoju Eye Care Holdings Limited (2219.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chaoju Eye Care Holdings Limited, a leading company in the Medical – Care Facilities industry within the Healthcare sector.
- European Sustainable Growth Acquisition Corp. (EUSGU) Income Statement Analysis – Financial Results
- Elevai Labs, Inc. Common Stock (ELAB) Income Statement Analysis – Financial Results
- Alderan Resources Limited (AL8.AX) Income Statement Analysis – Financial Results
- Gladstone Land Corporation (LANDP) Income Statement Analysis – Financial Results
- EuroSite Power Inc. (EUSP) Income Statement Analysis – Financial Results
Chaoju Eye Care Holdings Limited (2219.HK)
About Chaoju Eye Care Holdings Limited
Chaoju Eye Care Holdings Limited owns and operates a network of ophthalmic hospitals and optical centers in China. Its consumer ophthalmic services include treatments and prevention for various ophthalmic disorders, such as refractive and presbyopia correction, and myopia control, as well as optical products and services. The company also provides basic ophthalmic services, including cataract, glaucoma, ocular fundus diseases, ocular muscle diseases, refraction errors, pediatric ophthalmology, ocular surface diseases, lacrimal diseases, orbital diseases, oculoplastic, and ocular trauma. As of December 31, 2021, it operated a network of 17 ophthalmic hospitals, 24 optical centers, and 2 clinics in Zhejiang, Jiangsu, Shanxi, and Hebei provinces, as well as in Inner Mongolia. The company was founded in 1988 and is headquartered in Beijing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.37B | 990.04M | 997.79M | 794.28M | 714.67M | 632.66M |
| Cost of Revenue | 748.37M | 555.35M | 549.11M | 444.80M | 436.60M | 387.70M |
| Gross Profit | 621.13M | 434.70M | 448.67M | 349.48M | 278.07M | 244.96M |
| Gross Profit Ratio | 45.35% | 43.91% | 44.97% | 44.00% | 38.91% | 38.72% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 222.46M | 162.04M | 177.28M | 43.50M | 33.20M | 37.30M |
| Selling & Marketing | 104.99M | 61.28M | 47.15M | 32.89M | 34.53M | 35.86M |
| SG&A | 327.45M | 223.32M | 224.43M | 76.39M | 67.73M | 73.16M |
| Other Expenses | 0.00 | -4.38M | -2.28M | 88.47M | 83.12M | -9.12M |
| Operating Expenses | 317.86M | 218.95M | 222.15M | 164.86M | 150.85M | 164.80M |
| Cost & Expenses | 1.10B | 774.30M | 771.26M | 609.66M | 587.45M | 552.50M |
| Interest Income | 41.31M | 22.97M | 8.33M | 4.60M | 6.71M | 6.80M |
| Interest Expense | 12.22M | 11.90M | 10.54M | 12.75M | 22.87M | 24.32M |
| Depreciation & Amortization | 123.36M | 99.37M | 83.52M | 77.25M | 76.24M | 71.82M |
| EBITDA | 434.82M | 234.40M | 304.65M | 259.78M | 191.17M | 143.54M |
| EBITDA Ratio | 31.75% | 23.68% | 31.90% | 32.71% | 28.84% | 23.54% |
| Operating Income | 303.28M | 255.59M | 234.73M | 182.53M | 129.84M | 80.16M |
| Operating Income Ratio | 22.14% | 25.82% | 23.53% | 22.98% | 18.17% | 12.67% |
| Total Other Income/Expenses | -4.03M | 23.39M | -15.95M | -27.01M | -35.13M | -32.76M |
| Income Before Tax | 299.24M | 239.14M | 210.58M | 157.62M | 92.06M | 47.40M |
| Income Before Tax Ratio | 21.85% | 24.15% | 21.10% | 19.84% | 12.88% | 7.49% |
| Income Tax Expense | 78.51M | 55.94M | 52.94M | 37.09M | 21.24M | 18.20M |
| Net Income | 228.91M | 187.75M | 161.75M | 124.14M | 75.65M | 38.71M |
| Net Income Ratio | 16.72% | 18.96% | 16.21% | 15.63% | 10.59% | 6.12% |
| EPS | 0.33 | 0.27 | 0.26 | 0.18 | 0.11 | 0.06 |
| EPS Diluted | 0.33 | 0.27 | 0.26 | 0.18 | 0.11 | 0.06 |
| Weighted Avg Shares Out | 695.61M | 706.44M | 624.52M | 687.50M | 687.50M | 687.50M |
| Weighted Avg Shares Out (Dil) | 696.73M | 706.44M | 624.52M | 687.50M | 687.50M | 687.50M |
Source: https://incomestatements.info
Category: Stock Reports